Profile data is unavailable for this security.
About the company
Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
- Revenue in USD (TTM)5.10bn
- Net income in USD-360.00m
- Incorporated2020
- Employees13.00k
- LocationBausch + Lomb Corp520 Applewood CrescentVAUGHAN L4K 4B4CanadaCAN
- Websitehttps://ir.bausch.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LivaNova PLC | 1.39bn | -242.47m | 3.84bn | 3.30k | -- | 3.20 | -- | 2.77 | -4.47 | -4.47 | 25.37 | 21.96 | 0.543 | 2.84 | 6.79 | 420,622.10 | -9.48 | -3.21 | -12.39 | -3.97 | 68.04 | 68.27 | -17.46 | -6.55 | 1.16 | 3.67 | 0.2389 | -- | 10.74 | 8.24 | -483.45 | -- | 18.27 | -- |
| iRhythm Holdings, Inc | 747.14m | -44.55m | 4.15bn | 2.40k | -- | 27.16 | -- | 5.56 | -1.41 | -1.41 | 23.35 | 4.73 | 0.7657 | 12.33 | 9.60 | 311,307.50 | -4.57 | -16.40 | -5.28 | -19.65 | 70.57 | 68.67 | -5.96 | -19.44 | 4.48 | -- | 0.8096 | -- | 26.24 | 23.02 | 60.67 | -- | 27.88 | -- |
| Merit Medical Systems Inc | 1.52bn | 128.49m | 4.55bn | 7.50k | 35.99 | 2.87 | 17.85 | 3.00 | 2.13 | 2.13 | 25.07 | 26.66 | 0.594 | 2.43 | 7.70 | 202,120.80 | 5.03 | 4.56 | 5.53 | 5.10 | 48.70 | 46.73 | 8.48 | 7.34 | 2.95 | 16.77 | 0.3166 | 0.00 | 11.75 | 9.48 | 6.76 | -- | 11.48 | -- |
| Stevanato Group SpA | 1.37bn | 164.31m | 4.57bn | 5.52k | 25.07 | 2.45 | 17.44 | 3.34 | 0.602 | 0.602 | 5.01 | 6.16 | 0.5058 | 2.95 | 2.65 | 247,752.80 | 6.08 | 8.02 | 7.63 | 10.94 | 29.27 | 31.01 | 12.01 | 13.24 | 1.30 | 30.00 | 0.2386 | 6.82 | 1.72 | 15.53 | -19.13 | 24.61 | 33.52 | -- |
| Envista Holdings Corp | 2.72bn | 47.00m | 4.82bn | 12.00k | 107.07 | 1.55 | 29.60 | 1.77 | 0.275 | 0.275 | 16.10 | 18.96 | 0.4931 | 4.62 | 6.86 | 226,625.00 | 0.8523 | -2.14 | 1.01 | -2.58 | 55.02 | 56.70 | 1.73 | -5.21 | 2.04 | 6.70 | 0.318 | -- | 8.32 | 7.11 | 104.20 | 2.03 | -1.03 | -- |
| Lantheus Holdings Inc | 1.54bn | 233.56m | 4.93bn | 1.19k | 22.69 | 4.52 | 16.23 | 3.20 | 3.36 | 3.36 | 22.33 | 16.87 | 0.7328 | 9.04 | 4.53 | 1,292,212.00 | 11.10 | 11.26 | 12.85 | 12.98 | 61.10 | 61.61 | 15.15 | 14.47 | 2.51 | -- | 0.3432 | 0.00 | 0.5019 | 35.35 | -25.25 | -- | 23.67 | -- |
| TransMedics Group Inc | 605.49m | 188.99m | 5.04bn | 898.00 | 30.88 | 10.65 | 23.31 | 8.33 | 4.76 | 4.79 | 14.94 | 13.81 | 0.6467 | 5.09 | 6.65 | 674,269.50 | 20.19 | 4.75 | 21.93 | 5.18 | 59.92 | 61.27 | 31.21 | 8.52 | 6.59 | 84.70 | 0.5199 | 0.00 | 37.13 | 88.21 | 436.58 | -- | 164.81 | -- |
| Teleflex Inc | 2.39bn | 58.53m | 5.43bn | 15.50k | 99.15 | 1.74 | 23.00 | 2.27 | 1.24 | -20.56 | 53.59 | 70.70 | 0.341 | 2.23 | 5.95 | 154,489.00 | 0.8335 | 3.12 | 0.9266 | 3.43 | 53.13 | 57.05 | 2.44 | 10.06 | 2.01 | 2.73 | 0.4581 | 28.48 | 17.25 | -4.72 | 2.34 | -29.49 | 0.9821 | 0.00 |
| Caris Life Sciences Inc | -100.00bn | -100.00bn | 5.84bn | -- | -- | 12.18 | -- | -- | -- | -- | -- | 1.70 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 9.36 | -- | 0.4404 | -- | 34.67 | -- | 18.22 | -- | -- | -- |
| Avantor Inc | 6.55bn | -530.20m | 6.01bn | 13.50k | -- | 1.08 | -- | 0.9171 | -0.7775 | -0.7775 | 9.62 | 8.16 | 0.5481 | 5.70 | 6.21 | 485,348.20 | -4.44 | 2.78 | -5.17 | 3.18 | 32.65 | 33.77 | -8.09 | 5.00 | 1.18 | 3.62 | 0.4149 | 0.00 | -3.41 | 0.4913 | -174.52 | -- | 15.90 | -- |
| Bruker Corp | 3.44bn | -22.50m | 6.06bn | 11.09k | -- | 2.47 | 30.44 | 1.76 | -0.1485 | -0.1485 | 22.63 | 16.15 | 0.5705 | 1.64 | 5.22 | 310,013.50 | -0.1212 | 5.07 | -0.1553 | 6.76 | 47.13 | 49.70 | -0.2124 | 7.56 | 0.8553 | 9.30 | 0.4268 | 13.19 | 2.08 | 11.57 | -119.89 | -- | 4.34 | 4.56 |
| Bausch + Lomb Corp | 5.10bn | -360.00m | 6.52bn | 13.00k | -- | 1.01 | 94.53 | 1.28 | -1.02 | -1.02 | 14.42 | 18.20 | 0.3711 | 2.04 | 4.54 | 392,384.60 | -2.56 | -1.13 | -2.97 | -1.29 | 59.81 | 60.36 | -6.90 | -3.23 | 1.04 | 0.4434 | 0.4381 | -- | 6.47 | 8.38 | -13.56 | -- | 6.65 | -- |
| Glaukos Corp | 507.44m | -187.69m | 7.03bn | 1.09k | -- | 10.62 | -- | 13.86 | -3.27 | -3.27 | 8.87 | 11.41 | 0.5432 | 1.84 | 5.99 | 463,840.90 | -20.09 | -12.56 | -22.19 | -13.55 | 77.97 | 76.60 | -36.99 | -34.64 | 4.06 | -- | 0.094 | -- | 32.33 | 17.67 | -28.23 | -- | 28.47 | -- |
| Repligen Corp | 738.26m | 48.89m | 7.04bn | 2.00k | 144.59 | 3.34 | 55.15 | 9.54 | 0.8643 | 0.8643 | 13.05 | 37.39 | 0.2555 | 2.23 | 5.04 | 369,128.00 | 1.69 | 2.88 | 1.77 | 3.20 | 52.65 | 53.58 | 6.62 | 10.73 | 7.12 | -- | 0.2047 | 0.00 | 16.36 | 15.05 | 291.64 | -3.99 | -0.4706 | -- |
| Bio Rad Laboratories Inc | 2.58bn | 759.90m | 7.49bn | 7.45k | 10.02 | 1.01 | 8.10 | 2.90 | 27.91 | 27.91 | 94.69 | 276.16 | 0.2591 | 1.65 | 5.66 | 346,738.30 | 7.62 | -1.69 | 8.02 | -1.77 | 52.01 | 54.52 | 29.42 | -8.08 | 4.19 | -- | 0.139 | -- | 0.6507 | 0.2935 | 141.20 | -27.58 | 7.74 | -- |
| Masimo Corp | 1.53bn | 207.70m | 9.16bn | 2.20k | 45.25 | 12.67 | 37.16 | 6.00 | 3.88 | -2.77 | 28.42 | 13.84 | 0.7062 | 1.39 | 4.42 | 694,045.40 | 9.61 | 5.65 | 12.45 | 6.99 | 61.90 | 58.51 | 13.60 | 9.43 | 1.47 | 8.39 | 0.421 | 0.00 | 9.44 | 5.95 | 1,182.10 | -2.87 | -20.94 | -- |
Data as of Mar 03 2026. Currency figures normalised to Bausch + Lomb Corp's reporting currency: US Dollar USD
6.55%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Deutsche Bank Securities, Inc.as of 31 Dec 2025 | 3.45m | 0.97% |
| Oaktree Capital Management LPas of 31 Dec 2025 | 3.38m | 0.96% |
| D. E. Shaw & Co. LPas of 31 Dec 2025 | 2.85m | 0.80% |
| GoldenTree Asset Management LPas of 31 Dec 2025 | 2.66m | 0.75% |
| Silver Point Capital LPas of 31 Dec 2025 | 2.57m | 0.72% |
| Caspian Capital LPas of 31 Dec 2025 | 2.00m | 0.56% |
| Davidson Kempner Capital Management LPas of 31 Dec 2025 | 1.94m | 0.55% |
| Glenview Capital Management LLCas of 31 Dec 2025 | 1.65m | 0.47% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2025 | 1.45m | 0.41% |
| Nomura Global Financial Products, Inc.as of 31 Dec 2025 | 1.26m | 0.36% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
